"Reducing the timeframes even at one stage of development

[tanjimajuha20]

This was stated by Vasily Ignatyev, CEO of JSC R-Pharm, at the Future Technologies Forum. According to him, the use of AI in the pharmaceutical industry provides an advantage at all stages of drug development, namely, it makes it possible to process a large array of data, model new molecular structures and simulate the behavior of the drug in the human body.

"The main focus of the work is to accelerate the development of drugs by selecting optimal configurations, predicting the behavior of molecules in the body and identifying new properties of existing drugs," he said.

The R-Pharm Research brazil whatsapp number database Laboratory and the Sber Artificial Intelligence Laboratory chose the CD137 receptor as the object of study - it activates the tumor necrosis factor to stimulate the immune system in the fight against melanoma, lung cancer, kidney cancer and lymphoma. As a result of their joint work, AIRI's artificial intelligence proposed a set of promising drug candidates - dozens of selected molecules. Then, the researchers in the laboratory conducted tests and confirmed the hypotheses that the AI ​​had previously put forward based on data analysis.

"Usually, it takes three years out of the 15 years of the entire drug development process to find and optimize candidates - from the emergence of its idea to its launch on the market. This is global statistics. We have accelerated the three-year stage of research work three times - to one year. Acceleration and optimization of drug development with the help of AI are also possible at other stages, thanks to which the period from a scientific idea to real medical practice can be reduced by two to three times in the coming years," said Vasily Ignatyev.

will lead to new, more effective and safe drugs being available earlier and cheaper, since a significant part of the justification for the price of a drug is the cost of research and development. At this stage, on average, one out of 100 drug candidates reaches the market. When using AI, the success rate will be higher and, accordingly, the availability and speed of innovations entering the market will increase," noted Vasily Ignatiev.

According to him, R-Pharm, Sber and AIRI continue to work on other drugs, including those that prevent Alzheimer's disease and slow its progression.

Viktor Dubrovin, CEO of the Nearmedic clinic network, believes that AI and digitalization are the main driver of the development of import substitution in the pharmaceutical industry and in medicine in general: "Technologies will reduce costs for the development of new molecules, research, and the creation of new drugs. Exactly the same process is happening in medicine. Thanks to AI, we reduce the costs of patients, clinics, and ultimately healthcare for the treatment of patients."

"I see great potential for using AI where there is the greatest number of medical errors: signal and image processing, as well as areas of decision-making in situations where there is a great temptation to get rid of the patient quickly, for example, screening," added Mikhail Elyanov, President of the Association for the Development of Medical Information Technologies (ARMIT).

In 2019, Sber initiated the creation of the Artificial Intelligence Alliance, which united technology companies for the joint development of their competencies and the accelerated implementation of AI in education, scientific research and practical business activities. The companies participating in the alliance are Sber, Gazprom Neft, Yandex, VK Group, MTS, the Russian Direct Investment Fund, etc.

"Sberbank" is creating an industry group for the implementation and development of AI in medicine within the AI ​​Alliance. We will discuss unified metrics, standardization for the creation of new AI models, as well as personnel training," said Sergey Zhdanov, Managing Director and Director of the Health Industry Center of PJSC Sberbank, at the Future Technologies Forum.